Roivant Sciences Ltd. (ROIV) Fair Value 2026

ROIV · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.6 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (36/100)

Quick Summary — As of 2026-08-28, Roivant Sciences Ltd. (ROIV) trades at $34.71. QOC: 5.6/10. Value Trap Risk: 36/100 (LOW). 0/13 models active.

Key Facts

Ticker
ROIV
Price
$34.71
Quality Score
5.6/10
Value Trap Risk
36/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give ROIV?

0 Intrinsic Value Models vs. Current Price ($34.71)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Roivant Sciences Ltd. (ROIV) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Roivant Sciences Ltd. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About ROIV?

0 of 13 models are currently active for ROIV. See which stocks rank higher →

How Does ROIV Rank in Biotechnology?

Among 625 Biotechnology stocks, ROIV ranks #196 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotechnology enterprise businesses. For Roivant Sciences Ltd., metrics like R&D burn rate provide important context that general-purpose valuation models may underweight.

Is ROIV a Value Trap?

CirclFi's Value Trap algorithm assigns ROIV a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Roivant Sciences Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Roivant Sciences Ltd. scores 5.6 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ROIV valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Roivant Sciences Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

IVAInventiva S.A.QOC 5.6UPBUpstream Bio, Inc.QOC 5.6OVIDOvid Therapeutics Inc.QOC 5.7AUTLAutolus Therapeutics plcQOC 5.6WHWKWhitehawk Therapeutics, Inc.QOC 5.7CYCNCyclerion Therapeutics, Inc.QOC 5.6PLRXPliant Therapeutics, Inc.QOC 4.9AGTXAgentix Corp.QOC 4.2TLXTelix Pharmaceuticals LimitedQOC 7.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: IVA · UPB · OVID · AUTL · WHWK · CYCN · PLRX · AGTX · TLX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ROIV?

5 companies across all industries closest to ROIV’s Quality of Company score of 5.6/10.

XRXXerox Holdings CorporationQOC 5.6CUPRCuprina Holdings (Cayman) LimitedQOC 5.6DTIDrilling Tools International CorporationQOC 5.6CTEVClaritev CorporationQOC 5.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: XRX · CUPR · DTI · CTEV · NVDA

Where Does ROIV Sit in CirclFi's Biotechnology Rankings?

ROIV is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Roivant Sciences Ltd.’s Valuation?

What is Roivant Sciences Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Roivant Sciences Ltd. (ROIV). The Quality of Company score is 5.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ROIV overvalued or undervalued right now?

At $34.71, 0 of 0 active models suggest ROIV may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Roivant Sciences Ltd.'s business model in Biotechnology.

What does a Quality of Company score of 5.6 mean for ROIV?

Roivant Sciences Ltd.'s QOC of 5.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ROIV?

CirclFi analyzes ROIV with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is ROIV a value trap in 2026?

Roivant Sciences Ltd.'s Value Trap score is 36/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Roivant Sciences Ltd. (ROIV) a Quality of Company score of 5.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/ROIV/ · Methodology
Primary sources for this ROIV valuation
  • Financial statements: Roivant Sciences Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001635088) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ROIV as of ; valuations recomputed .